<DOC>
	<DOCNO>NCT01381055</DOCNO>
	<brief_summary>The purpose study determine whether pentoxifylline associate pentavalent antimony high cure rate pentavalent antimony alone treatment cutaneous leishmaniasis .</brief_summary>
	<brief_title>Antimony Plus Pentoxifylline Cutaneous Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<criteria>Newly diagnose ( untreated ) cutaneous leishmaniasis localize lesion positive culture diagnose polymerase chain reaction ( PCR ) method intradermal skin testing ( Montenegro test ) . Number lesion : 1 3 ulcerative lesion . LesionÂ´s diameter : 1 5 cm . Disease duration : three month . Safety concern : AST , ALT &gt; 3 time upper limit normal range Serum creatinine BUN &gt; 1.5 time upper limit normal range Evidence serious underlie disease ( cardiac , renal , hepatic pulmonary ) Immunodeficiency antibody HIV Any noncompensated uncontrolled condition , active tuberculosis , malignant disease , severe malaria , HIV , major infectious disease Lactation , pregnancy ( determined adequate test ) inadequate contraception female childbearing potential treatment period plus 2 month Lack suitability trial : Negative parasitology ( aspirate/biopsy/PCR ) negative Montenegro test Any history prior antileishmania therapy Any condition compromise ability comply study procedure Administrative reason : Lack ability willingness give inform consent ( patient and/or parent / legal representative ) Anticipated nonavailability study visits/procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>Pentoxifylline</keyword>
	<keyword>Meglumine antimoniate</keyword>
	<keyword>L. braziliensis</keyword>
</DOC>